TY - JOUR T1 - Burden of Multiple Sclerosis in Eastern Mediterranean Region (1990-2016): Findings From the 2016 Global Burden of Disease Study JF - medRxiv DO - 10.1101/19005918 SP - 19005918 AU - Mohammad Ali Sahraian AU - Pouria Heydarpour AU - Maziar Moradi-Lakeh AU - Sharareh Eskandarieh AU - Seyed-Mohammad Fereshtehnejad AU - Kia Vosughi AU - Vafa Rahimi-Movaghar AU - Farshad Farzadfar AU - Reza Malekzadeh AU - Theo Vos AU - Valery Feigin AU - Mohsen Naghavi AU - Ali H. Mokdad Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/09/16/19005918.abstract N2 - Background Multiple sclerosis (MS) is among the leading causes of disability in Young Adults worldwide. Current estimates of MS burden in Eastern Mediterranean Region (EMR) are necessary for planning effective interventions .To estimate Prevalence, incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs) and disability-adjusted life-years (DALYs) in EMR by country age, and sex from 1990 to 2016.Methods We estimated regional and country-specific prevalence, incidence, mortality, DALYs, YLLs, and YLDs for MS. DALYs were computed as the sum of YLDs and YLLs.Results Total DALYs in EMR countries was 12,810 in 1990 for males and increased to 36,391 in 2016 and from 18,962 to 53,851 for females. Lowest DALYs in both sexes were observed in Somalia (248) while the highest were in Iran (26,394). YLDs in males increased from 6,511 in 1990 to 19,515 in 2016, and in females from 12,247 to 33,937. The highest age-standardized prevalence, incidence, YLDs and DALYs were in Iran (72.11, 2.49, 18.03, and 32.5, respectively).Conclusions Our findings provide valuable information to guide the development and implementation of measures to address the rising burden of MS and it consequences in the EMR countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by TUMS grant.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAll data provided by Institute of Health Metrics and Evaluation is available below. https://figshare.com/articles/Burden_of_MS_in_EMR/7692389 https://figshare.com/articles/Burden_of_MS_in_EMR/7692389 ER -